



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 07 2003
TECH CENTER 1600/2900
#1
4
5/12

In re application of

Docket No: Q68584

Hiroyuki HIRAI, et al.

Appln. No.: 10/069,148

Group Art Unit: 1621

Confirmation No.: 7696

Examiner: Not Yet Assigned

Filed: June 24, 2002

For: METHOD OF IDENTIFYING PROPERTIES OF SUBSTANCE WITH RESPECT TO
PROSTAGLANDIN D RECEPTORS

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a


INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/069,148

request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required. Nevertheless, since a Statement can be made, a Statement is submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Bruce E. Kramer
Registration No. 33,725

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

Date: May 6, 2003

Application Number	10/069,148
Confirmation Number	7696
Filing Date	June 24, 2003
First Named Inventor	Hiroyuki HIRAI
Art Unit	1621
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q68584

Application Number	10/069,148
--------------------	------------

Confirmation Number	7696
---------------------	------

Filing Date	June 24, 2003
-------------	---------------

First Named Inventor	Hirovuki HIRAI
----------------------	----------------

Art Unit	1621
----------	------

Examiner Name	Not Yet Assigned
---------------	------------------

Attorney Docket Number	Q68584
------------------------	--------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1	of	1
---	----	---

[illegible][illegible]

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		BOIE YVES ET AL: "Molecular cloning and characterization of the human prostanoid DP receptor." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 32, 1995, pages 18910-18916. XP002230274 ISSN: 0021-9258	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q68584

Hiroyuki HIRAI, et al.

Appln. No.: 10/069,148

Group Art Unit: 1621

Confirmation No.: 7696

Examiner: Not Yet Assigned

Filed: June 24, 2003

For: **METHOD OF IDENTIFYING PROPERTIES OF SUBSTANCE WITH RESPECT TO PROSTAGLANDIN D RECEPTORS**

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

Bruce E. Kramer
Registration No. 33,725

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

Date: May 6, 2003

RECEIVED

MAY 07 2003

TECH CENTER 1600/2900